

H₂ injection aids diabetes outcomes in animal model

May 3 2017



(HealthDay)—Subcutaneous injection of H₂ significantly improves type

2 diabetes mellitus (T2DM)-related outcomes in a mouse model, according to a study published online April 8 in the *Journal of Diabetes Investigation*.

Xiaolong Zhang, from the Second Affiliated Hospital of Wenzhou Medical University in China, and colleagues evaluated whether subcutaneous injection of H₂ (1 mL/mouse/week for four weeks) shows enhanced efficacy against T2DM induced in mice by a high-fat diet and low-dose streptozotocin treatment.

The researchers found that the body weight of H₂-treated mice did not change over the study period. Glucose, insulin, low-density lipoprotein, and triglyceride levels in serum were significantly lower in treated mice versus untreated controls, while high-density lipoprotein cholesterol in the serum was significantly higher. In H₂-treated [mice](#), both [glucose tolerance](#) and insulin sensitivity were improved. H₂ treatment also lead to significant reductions in urine volume, urinary total protein and β2 microglobulin, kidney/body weight ratio, and kidney fibrosis, in diabetic nephropathy analysis.

"Subcutaneous injection of H₂ significantly improves T2DM and diabetic nephropathy related outcomes in a [mouse model](#), supporting further consideration of subcutaneous [injection](#) as a novel and effective route of clinical H₂ administration," the authors write.

More information: [Abstract](#)
[Full Text](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: H2 injection aids diabetes outcomes in animal model (2017, May 3) retrieved 18 April 2024 from <https://medicalxpress.com/news/2017-05-h2-aids-diabetes-outcomes-animal.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.